Search Results

Elvitegravir 25 mg  | 99.73%

TargetMol

Elvitegravir is a Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor. The mechanism of action of elvitegravir is as an HIV Integrase Inhibitor, and Cytochrome P450 2C9 Inducer.

More Information Supplier Page

Elvitegravir 5 mg  | 99.73%

TargetMol

Elvitegravir is a Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor. The mechanism of action of elvitegravir is as an HIV Integrase Inhibitor, and Cytochrome P450 2C9 Inducer.

More Information Supplier Page

Pilaralisib 2 mg  | 98.24%

TargetMol

Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Glioblastoma, and Breast Cancer, among others.

More Information Supplier Page

ID-8 200 mg  | Purity Not Available

TargetMol

ID-8, a DYRK inhibitor, sustains embryonic stem cell self-renewal in long-term culture.

More Information Supplier Page

ID-8 100 mg  | Purity Not Available

TargetMol

ID-8, a DYRK inhibitor, sustains embryonic stem cell self-renewal in long-term culture.

More Information Supplier Page

Edoxaban 100 mg  | Purity Not Available

TargetMol

Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with K i s of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and is able to be used for stroke prevention. Edoxaban is a also weak inhibitor of thrombin and factor IXaβ (FIXa), […]

More Information Supplier Page